SMCR7 CRISPR/Cas9 KO Plasmid (h): sc-406975
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SMCR7 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SMCR7 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SMCR7 CRISPR/Cas9 KO Plasmid (h) | sc-406975 | 20 µg | $397.00 |
Overview
MIEF2 encodes the mitochondrial elongation factor 2 protein (SMCR7/MiD51), an outer mitochondrial membrane adaptor that regulates mitochondrial fission by recruiting and organizing the GTPase DRP1. Through control of mitochondrial network architecture, MIEF2 influences oxidative phosphorylation efficiency, reactive oxygen species balance, and mitochondrial quality control pathways such as mitophagy, thereby impacting cellular metabolism and stress responses. Altered MIEF2 activity has been associated with dysregulated mitochondrial dynamics observed in neurodegeneration, cardiometabolic dysfunction, and cancer-related metabolic reprogramming. As a node linking organelle morphology to bioenergetic signaling, MIEF2 is frequently investigated in studies of apoptosis susceptibility, innate immune signaling from mitochondria, and adaptation to hypoxia or nutrient stress.
SMCR7 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MIEF2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MIEF2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MIEF2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SMCR7 protein expression.
This CRISPR knockout system enables efficient generation of MIEF2-deficient cell models for investigation of SMCR7 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MIEF2 exon(s) critical for SMCR7 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MIEF2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SMCR7 CRISPR/Cas9 KO Plasmid (h) and SMCR7 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MIEF2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SMCR7 HDR Plasmid (h) and SMCR7 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MIEF2 homology arms to support homology-directed repair at defined MIEF2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.